PIRS Stock Overview
Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Pieris Pharmaceuticals, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.21 |
52 Week High | US$1.52 |
52 Week Low | US$0.14 |
Beta | 0.47 |
1 Month Change | 34.44% |
3 Month Change | 33.93% |
1 Year Change | -82.64% |
3 Year Change | -92.55% |
5 Year Change | -93.23% |
Change since IPO | -91.92% |
Recent News & Updates
Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Not Doing Enough For Some Investors As Its Shares Slump 27%
Dec 18We Think Pieris Pharmaceuticals (NASDAQ:PIRS) Needs To Drive Business Growth Carefully
Aug 18Recent updates
Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Not Doing Enough For Some Investors As Its Shares Slump 27%
Dec 18We Think Pieris Pharmaceuticals (NASDAQ:PIRS) Needs To Drive Business Growth Carefully
Aug 18Analysts Just Shaved Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Forecasts Dramatically
May 15Why Investors Shouldn't Be Surprised By Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) 41% Share Price Plunge
Apr 17Can Pieris Pharmaceuticals (NASDAQ:PIRS) Afford To Invest In Growth?
Dec 31Bearish: This Analyst Is Revising Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Revenue and EPS Prognostications
Aug 10Pieris Pharmaceuticals GAAP EPS of -$0.14 misses by $0.03, revenue of $3.7M misses by $6.77M
Aug 04Pieris: Early Stage Developer Of Novel Asset Class
Jan 09We're Not Very Worried About Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Rate
Dec 15Progress At Pieris Pharmaceuticals
Oct 27Analysts Just Made A Noticeable Upgrade To Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Forecasts
Aug 05We Think Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) CEO Compensation Package Needs To Be Put Under A Microscope
Jun 19Need To Know: Analysts Just Made A Substantial Cut To Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Estimates
May 22Will Pieris Pharmaceuticals (NASDAQ:PIRS) Spend Its Cash Wisely?
May 19Analysts Are Betting On Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) With A Big Upgrade This Week
Apr 01Here's What Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Shareholder Ownership Structure Looks Like
Mar 08We're Keeping An Eye On Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Rate
Feb 01How Much Did Pieris Pharmaceuticals'(NASDAQ:PIRS) Shareholders Earn From Share Price Movements Over The Last Three Years?
Dec 28How Does Pieris Pharmaceuticals' (NASDAQ:PIRS) CEO Salary Compare to Peers?
Dec 02Shareholder Returns
PIRS | US Biotechs | US Market | |
---|---|---|---|
7D | 23.5% | -2.1% | -0.1% |
1Y | -82.6% | 10.4% | 28.4% |
Return vs Industry: PIRS underperformed the US Biotechs industry which returned 10.4% over the past year.
Return vs Market: PIRS underperformed the US Market which returned 28.4% over the past year.
Price Volatility
PIRS volatility | |
---|---|
PIRS Average Weekly Movement | 10.4% |
Biotechs Industry Average Movement | 11.9% |
Market Average Movement | 6.1% |
10% most volatile stocks in US Market | 16.8% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: PIRS's share price has been volatile over the past 3 months.
Volatility Over Time: PIRS's weekly volatility has decreased from 17% to 10% over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2000 | 136 | Steve Yoder | https://www.pieris.com |
Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin based drug candidate, elarekibep used for the treatment of asthma; and PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis.
Pieris Pharmaceuticals, Inc. Fundamentals Summary
PIRS fundamental statistics | |
---|---|
Market cap | US$20.76m |
Earnings (TTM) | -US$28.06m |
Revenue (TTM) | US$47.36m |
0.4x
P/S Ratio-0.7x
P/E RatioIs PIRS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
PIRS income statement (TTM) | |
---|---|
Revenue | US$47.36m |
Cost of Revenue | US$50.73m |
Gross Profit | -US$3.37m |
Other Expenses | US$24.69m |
Earnings | -US$28.06m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.28 |
Gross Margin | -7.12% |
Net Profit Margin | -59.25% |
Debt/Equity Ratio | 0% |
How did PIRS perform over the long term?
See historical performance and comparison